Humacyte, Inc.

Stage 4 · Declining · week 14

As of Oct 22, 2026, Humacyte is in Stage 4, the downtrend phase, now in week 14 (since Jul 17, 2026). It closed at $0.41, 75.8% below its 52-week high and below its 200-day average, which is falling.

$0.41

+1.20% today

$115M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is HUMA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 15w

S4 30w

S4 41w

S4 14w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 2w → S2 6w → S3 2w → S4 9w → S1 8w → S2 10w → S3 1w → S2 15w → S3 3w → S2 1w → S3 8w → S4 30w → S1 9w → S4 41w → S1 6w → S4 14w current

Total tracked: 166 weeks across 16 stage runs.

HUMA among Biotechnology451st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…451	HUMAHumacyte, Inc.	Stage 4 · wk 14	13	−27.0%

vs 52W High

-75.8%

$0.35 lo$1.71 hi

75.8% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 14

1w13w26w

Week 14, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-50.1%

200 DMA: $0.83 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.30x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-27.0%

-33.9%

-41.7%

YTD

-57.6%

-76.1%

Scan Membership

Breakout Watch

Latest: 2024-09-18

6 appearances in last 60 days. First seen: 2021-09-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 14 · Vol 0.30x

2026-10-21S4

Wk 14 · Vol 0.55x

2026-10-20S4

Wk 14 · Vol 0.66x

2026-10-19S4

Wk 14 · Vol 0.63x

2026-10-16S4

Wk 13 · Vol 0.81x

2026-10-15S4

Wk 13 · Vol 2.99x

2026-10-14S4

Wk 13 · Vol 0.79x

2026-10-13S4

Wk 13 · Vol 1.84x

2026-10-12S4

Wk 13 · Vol 2.54x

2026-10-09S4

Wk 12 · Vol 1.36x

2026-10-08S4

Wk 12 · Vol 0.87x

2026-10-07S4

Wk 12 · Vol 0.62x

Moving averages & range

50 DMA

$0.55

200 DMA

$0.83

52W High

$1.71

52W Low

$0.35

5D Low

$0.40

Resistance levels (recent highs)

20d High

$0.56

60d High

$0.75

120d High

$1.49

250d High

$1.71

Next resistance

+34.9%

to 20d High

ROE

-547.9%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 3.7

Humacyte: quick answers

What stage is Humacyte in?

As of Oct 22, 2026, Humacyte (HUMA) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 17, 2026 and is in week 14. What the four stages mean

Is Humacyte in an uptrend?

No. Humacyte is in a Stage 4 downtrend. It trades 50.1% below its 200-day average, which is falling.

How far is Humacyte from its 52-week high?

Humacyte closed at $0.41 on Oct 22, 2026, 75.8% below its 52-week high of $1.71. Its 52-week low is $0.35.

How has Humacyte performed over the past year?

As of Oct 22, 2026, Humacyte is down 76.1% over the past year and down 57.6% so far in 2026.

Which sector and industry is Humacyte in?

Humacyte is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.